1 Department of Urology, Cleveland Clinic , Cleveland, Ohio.
2 Department of Immunology, Cleveland Clinic , Cleveland, Ohio.
J Endourol. 2018 Nov;32(11):995-1005. doi: 10.1089/end.2018.0294. Epub 2018 Oct 20.
Urinary stone disease (USD) has known associations with the gut microbiota. Approximately 80% of kidney stones contain oxalate as a primary constituent and diverse oxalate-degrading bacteria exist within the human gut, which may protect against USD. Although bacteriotherapy represents a promising strategy to eliminate oxalate and reduce the risk of USD, oxalate-degrading probiotics have had limited success. To identify limitations of oxalate-degrading probiotics and refine development of bacteriotherapies to prevent USD, we review the literature associated with the gut microbiota and USD.
A literature search was performed to identify publications that examine the role of oxalate-degrading bacteria or the whole gut microbiota in oxalate metabolism and the pathophysiology of USD. We conducted a meta-analysis of studies that examined the association of the whole gut microbiota with USD. In addition, we evaluated the gut microbiota of healthy individuals and those with comorbidities related to USD using publically available data from the American Gut Project (AGP).
Studies on Oxalobacter formigenes reveal that colonization by this species is not a good predictor of USD risk or urinary oxalate excretion. The species of oxalate-degrading bacteria used in probiotics and duration of administration do not impact efficacy or persistence. Studies focused on the whole gut microbiota reveal broad shifts in the gut microbiota associated with USD and a diverse microbial network is associated with oxalate metabolism. AGP data analysis demonstrated a strong overlap in microbial genera depleted in diseased individuals among USD and comorbidities.
The associations between the gut microbiota and USD extend beyond individual functional microbial species. Common shifts in the gut microbiota may facilitate the onset of USD and/or comorbidities. The successful development of bacteriotherapies to inhibit USD will need to incorporate strategies that target a broad diversity of bacteria rather than focus on a few specialist species.
尿路结石病(USD)与肠道微生物群有已知的关联。大约 80%的肾结石含有草酸作为主要成分,而人类肠道中存在着多种草酸降解细菌,这些细菌可能有助于预防 USD。尽管细菌疗法是消除草酸和降低 USD 风险的一种很有前途的策略,但草酸降解益生菌的应用效果有限。为了确定草酸降解益生菌的局限性,并改进预防 USD 的细菌疗法的开发,我们回顾了与肠道微生物群和 USD 相关的文献。
进行了文献检索,以确定检查草酸降解细菌或整个肠道微生物群在草酸代谢和 USD 病理生理学中作用的出版物。我们对检查整个肠道微生物群与 USD 之间关联的研究进行了荟萃分析。此外,我们使用美国肠道计划(AGP)的公开数据评估了健康个体和与 USD 相关的合并症个体的肠道微生物群。
关于产甲酸草酸杆菌的研究表明,该物种的定植并不能很好地预测 USD 风险或尿草酸排泄。益生菌中使用的草酸降解细菌的种类和给药时间长短都不会影响疗效或持久性。针对整个肠道微生物群的研究揭示了与 USD 相关的肠道微生物群的广泛变化,以及与草酸代谢相关的多样化微生物网络。AGP 数据分析表明,USD 和合并症患者中消耗的微生物属之间存在很强的重叠。
肠道微生物群与 USD 之间的关联不仅限于单个功能微生物物种。肠道微生物群的常见变化可能促进 USD 和/或合并症的发生。成功开发抑制 USD 的细菌疗法需要将策略纳入到靶向广泛多样性的细菌中,而不是专注于少数专门的物种。